Scarica l'app Stockscreener
1.995
4.52%
-0.105
Precedente Chiudi:
$2.10
Aprire:
$2.04
Volume 24 ore:
231.66K
Relative Volume:
0.35
Capitalizzazione di mercato:
$6.30M
Reddito:
$2.45M
Utile/perdita netta:
$-5.47M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-6.05M
1 W Prestazione:
-19.80%
1M Prestazione:
-65.31%
6M Prestazione:
-98.52%
1 anno Prestazione:
-99.65%
Intervallo 1D:
$1.94
$2.15
Intervallo di 1 settimana:
$1.7402
$2.60
Portata 52W:
$1.7402
$778.00
Elevai Labs Inc Stock (ELAB) Company Profile
Nome
Elevai Labs Inc
Settore
Industria
Telefono
18667944940
Indirizzo
120 NEWPORT CENTER DRIVE, NEWPORT BEACH
Confronta ELAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ELAB
Elevai Labs Inc
|
1.995 | 6.30M | 2.45M | -5.47M | -6.05M | -59.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.78 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.60 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
618.67 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.19 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.58 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elevai Labs Inc Borsa (ELAB) Ultime notizie
Elevai Labs Inc. announced that it expects to receive $1 million in funding - Marketscreener.com
Elevai Labs Inc. Announces Executive Changes - Marketscreener.com
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology - Marketscreener.com
Elevai Labs, Inc. signed a license agreement to acquire a Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology from INmune Bio, Inc.. - Marketscreener.com
Elevai Labs Inc. Announces Management Changes - Marketscreener.com
Elevai Labs Inc. Announces Resignation of Hatem Abou-Sayed MD as Member of the Board of Directors and as Chief Medical Officer - Marketscreener.com
Elevai Labs, Inc. Enters into Licensing Agreement with Yuva Biosciences, Inc. to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products - Marketscreener.com
Elevai Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Elevai Labs announces 1-for-200 reverse stock split - Investing.com
Elevai Labs announces 1-for-200 reverse stock split By Investing.com - Investing.com Canada
ELEVAI Labs Inc trading halted, news pending - TipRanks
Elevai Labs Inc. adjusts shareholder meeting quorum By Investing.com - Investing.com Nigeria
Elevai Labs Inc. adjusts shareholder meeting quorum - Investing.com
Elevai Labs stock plunges to 52-week low of $0.02 By Investing.com - Investing.com South Africa
Elevai Labs stock plunges to 52-week low of $0.02 - Investing.com
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - GlobeNewswire
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - The Manila Times
Elevai Labs Announces 1-for-200 Reverse Split to Maintain Nasdaq Listing | ELAB Stock News - StockTitan
Elevai Labs Withdraws Stock Exchange Offer Due to DTC Technical Issues | ELAB Stock News - StockTitan
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023) - Simply Wall St
CORRECTIONElevai Labs Inc. - The Bakersfield Californian
Elevai Labs Reports Mixed Q3: 74.7% Margins, Revenue Dips 4.9% Amid $8M Offering | ELAB Stock News - StockTitan
Elevai Labs Inc (ELAB) Quarterly 10-Q Report - Quartzy
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update - GlobeNewswire
Elevai Labs granted extension to meet Nasdaq listing standards - Investing.com
Elevai Labs granted extension to meet Nasdaq listing standards By Investing.com - Investing.com Canada
Natural Gas (NGN23) Quote - The Globe and Mail
Carebook Technologies Inc (CRBKF) QuotePress Release - The Globe and Mail
Compugen (CGEN) Stock Surges Amidst Biotech Sector Volatility - GuruFocus.com
Elevai Labs announces update and extension of pending offer to exchange shares of common stock - MSN
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Elevai Labs strikes new executive agreements - Investing.com India
Elevai Labs strikes new executive agreements By Investing.com - Investing.com Nigeria
Columbia Sprtswr (COLM-Q) QuotePress Release - The Globe and Mail
Elevai Biosciences gears up for obesity drug IND submission By Investing.com - Investing.com Nigeria
Elevai Biosciences gears up for obesity drug IND submission - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., - GlobeNewswire
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity - Yahoo Finance UK
Elevai reports promising preclinical obesity treatment results By Investing.com - Investing.com South Africa
Elevai reports promising preclinical obesity treatment results - Investing.com
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity - The Manila Times
ELAB stock’s current quarter earnings estimates: What analysts predict? - US Post News
Elevai Labs Inc. Inc. (ELAB) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Metric Deep Dive: Understanding Elevai Labs Inc. (ELAB) Through its Ratios - The Dwinnex
Insider’s View: Deciphering Elevai Labs Inc. (ELAB)’s Financial Health Through Ratios - The Dwinnex
Views of Wall Street’s Leading Experts on Elevai Labs Inc. - SETE News
Elevai Labs Inc. [ELAB] is -94.09% lower this YTD. Is it still time to buy? - The DBT News
Elevai Labs Inc. (ELAB) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock - The Manila Times
Elevai Labs Inc. Commences Offer to Exchange Up to - GlobeNewswire
Elevai Labs Inc Azioni (ELAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):